Barclays
DRUG

Barclays’s Bright Minds Biosciences DRUG Stock Holding History

Barclays’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Sell
3,077
-6,583
-68% -$530K ﹤0.01% 3618
2025
Q4 		$754K Buy
9,660
+3,079
+47% +$206K ﹤0.01% 3621
2025
Q3 		$399K Sell
6,581
-1,812
-22% -$70.3K ﹤0.01% 3943
2025
Q2 		$219K Buy
+8,393
New +$252K ﹤0.01% 4215

Other funds holding DRUG

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Barclays's DRUG Position: Q1 2026 in Review

Barclays reduced its Bright Minds Biosciences (DRUG) stake by 68% in Q1 2026, selling an estimated $530K and leaving 3,077 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.

Barclays first reported a position in DRUG in Q2 2025 and has held it in 4 quarters since. The position peaked at $754K in Q4 2025. 94 funds tracked by Wall St. Rank hold DRUG as of Q1 2026.

  • Barclays held 3,077 shares of Bright Minds Biosciences worth $225K as of Q1 2026.
  • Barclays sold 6,583 Bright Minds Biosciences shares in Q1 2026, an estimated $530K.
  • Bright Minds Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3618 holding.
  • Barclays first reported a position in Bright Minds Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Barclays's Bright Minds Biosciences position peaked at $754K in Q4 2025.
  • 94 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.